Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 253

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 253
---
 time by the board of directors prior to allocating to the holders 
 of ordinary shares. In any event, such dividends to be allocated to the holders of preference  
 shares shall not exceed 15% of the total amount of dividends declared from time to time;       |

| (b) | After                                                                                    
 allocation of dividends as per (a) above, the rest of the dividends shall be distributed 
 equally amongst the holders of ordinary shares according to their shareholding ratio;    |

| (c) | The                                                                                                
 holders of preferred shares shall be entitled to dividends only in respect of the years            
 for which the Company has declared a dividend payment, and there shall be no cumulative dividends; 
 and                                                                                                |

| (d) | Dividends                                                                                 
 allocated to the holders of preferred shares in each year shall be limited at the rate as 
 stated in (a) only. No additional dividends shall be paid to the holders of preferred     
 shares.                                                                                   |

Based upon the management’s
judgement on the Shares Structure, as the Company is able to exercise majority voting power in any board meeting, the Company accounts
for Med Holdings and FFC as subsidiaries on the ground that the Company is able to control Med Holdings and FFC by exercising its majority
voting power in any board meetings.

On April 17, 2024, the Company
entered into a non-binding term sheet (the “Non-Binding Term Sheet”) with European Wellness Investment Holdings Limited (“EWIHL”)
for (i) the potential acquisition of the entire equity interest of EWIHL by the Company for a consideration of US$268,000,000 to be payable
by issuing 53,600,000 ordinary shares of the of the Company to the shareholder(s) of EWIHL or its associate and (ii) the fund-raising
activity by the Company from public or private shareholders, and in a form mutually acceptable to the parties, including structured equity
investment for up to US$30 million. On December 11, 2024, NewGenIvf announced its entry into a binding term sheet with European Wellness
Investment Holdings Limited (“EWIHL”) for the above proposed reverse merger, completion of which was subject to, among other
conditions, the completion of due diligence, the negotiation of a definitive agreement, and obtaining adequate financing.

On May 24, 2024, the Company
received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying